Tags

Type your tag names separated by a space and hit enter

Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan.
Intern Med. 2013; 52(9):939-46.IM

Abstract

OBJECTIVE

Although the major cause of morbidity and mortality in patients with diabetes mellitus (DM) is cardiovascular disease, DM is also associated with certain site-specific cancers. However, whether DM is associated with an increased risk of cancer of the digestive tract remains undetermined. A nationwide, population-based database in Taiwan was analyzed to explore the relationship between DM and cancer of the digestive organs.

METHODS

From 2000 to 2007, a study cohort consisting of 39,515 patients with newly diagnosed diabetes without a previous diagnosis of gastrointestinal (GI) cancer was identified from the National Health Insurance Research Database in Taiwan. A control cohort of 79,030 age- and sex-matched non-diabetic subjects was selected to compare the occurrence of GI malignancies between the two groups. The association between the incidence of GI cancers and the use of glucose-lowering therapies was also investigated.

RESULTS

During the 7-year follow-up period, GI cancers developed in 929 diabetic patients (2.35%) and 1,126 subjects (1.42%) in the comparison cohort. DM was associated with a 2.75-fold (95% confidence interval (CI), 2.51-3.02) higher risk of developing GI malignancy. Among GI cancers, the incidences of stomach (adjusted hazard ratio (HR), 1.49; 95% CI, 1.16-1.92), liver (adjusted HR, 2.65; 95% CI, 2.29-3.07), colon (adjusted HR, 1.58; 95% CI, 1.28-1.94) and pancreatic cancers (adjusted HR, 4.35; 95% CI, 2.93-6.47) were significantly increased in the patients with DM. An analysis of the effects of various glucose-lowering therapies in the diabetic patients revealed the use of α-glucosidase inhibitors to be associated with a lower risk of hepatic cancer (adjusted HR, 0.62; 95% CI, 0.4-0.94). Thiazolidinedione (TZD) treatment was associated with lower stomach (adjusted HR, 0.11; 95% CI, 0.02-0.82) and hepatic cancer risks (adjusted HR, 0.46; 95% CI, 0.29-0.73), while sulfonylurea use was associated with a lower colon cancer risk (adjusted HR, 0.74; 95% CI, 0.51-1.09) and a higher pancreatic cancer risk (adjusted HR, 2.36; 95% CI, 1.21-4.61).

CONCLUSION

Patients with DM have an increased risk of GI malignancy that may be affected by the use of different categories of glucose-lowering therapies.

Authors+Show Affiliations

Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23648711

Citation

Chiu, Chun-Chih, et al. "Increased Risk of Gastrointestinal Malignancy in Patients With Diabetes Mellitus and Correlations With Anti-diabetes Drugs: a Nationwide Population-based Study in Taiwan." Internal Medicine (Tokyo, Japan), vol. 52, no. 9, 2013, pp. 939-46.
Chiu CC, Huang CC, Chen YC, et al. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. Intern Med. 2013;52(9):939-46.
Chiu, C. C., Huang, C. C., Chen, Y. C., Chen, T. J., Liang, Y., Lin, S. J., Chen, J. W., Leu, H. B., & Chan, W. L. (2013). Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. Internal Medicine (Tokyo, Japan), 52(9), 939-46.
Chiu CC, et al. Increased Risk of Gastrointestinal Malignancy in Patients With Diabetes Mellitus and Correlations With Anti-diabetes Drugs: a Nationwide Population-based Study in Taiwan. Intern Med. 2013;52(9):939-46. PubMed PMID: 23648711.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. AU - Chiu,Chun-Chih, AU - Huang,Chin-Chou, AU - Chen,Yu-Chun, AU - Chen,Tzeng-Ji, AU - Liang,Ying, AU - Lin,Shing-Jong, AU - Chen,Jaw-Wen, AU - Leu,Hsin-Bang, AU - Chan,Wan-Leong, Y1 - 2012/03/01/ PY - 2013/5/8/entrez PY - 2013/5/8/pubmed PY - 2013/12/18/medline SP - 939 EP - 46 JF - Internal medicine (Tokyo, Japan) JO - Intern Med VL - 52 IS - 9 N2 - OBJECTIVE: Although the major cause of morbidity and mortality in patients with diabetes mellitus (DM) is cardiovascular disease, DM is also associated with certain site-specific cancers. However, whether DM is associated with an increased risk of cancer of the digestive tract remains undetermined. A nationwide, population-based database in Taiwan was analyzed to explore the relationship between DM and cancer of the digestive organs. METHODS: From 2000 to 2007, a study cohort consisting of 39,515 patients with newly diagnosed diabetes without a previous diagnosis of gastrointestinal (GI) cancer was identified from the National Health Insurance Research Database in Taiwan. A control cohort of 79,030 age- and sex-matched non-diabetic subjects was selected to compare the occurrence of GI malignancies between the two groups. The association between the incidence of GI cancers and the use of glucose-lowering therapies was also investigated. RESULTS: During the 7-year follow-up period, GI cancers developed in 929 diabetic patients (2.35%) and 1,126 subjects (1.42%) in the comparison cohort. DM was associated with a 2.75-fold (95% confidence interval (CI), 2.51-3.02) higher risk of developing GI malignancy. Among GI cancers, the incidences of stomach (adjusted hazard ratio (HR), 1.49; 95% CI, 1.16-1.92), liver (adjusted HR, 2.65; 95% CI, 2.29-3.07), colon (adjusted HR, 1.58; 95% CI, 1.28-1.94) and pancreatic cancers (adjusted HR, 4.35; 95% CI, 2.93-6.47) were significantly increased in the patients with DM. An analysis of the effects of various glucose-lowering therapies in the diabetic patients revealed the use of α-glucosidase inhibitors to be associated with a lower risk of hepatic cancer (adjusted HR, 0.62; 95% CI, 0.4-0.94). Thiazolidinedione (TZD) treatment was associated with lower stomach (adjusted HR, 0.11; 95% CI, 0.02-0.82) and hepatic cancer risks (adjusted HR, 0.46; 95% CI, 0.29-0.73), while sulfonylurea use was associated with a lower colon cancer risk (adjusted HR, 0.74; 95% CI, 0.51-1.09) and a higher pancreatic cancer risk (adjusted HR, 2.36; 95% CI, 1.21-4.61). CONCLUSION: Patients with DM have an increased risk of GI malignancy that may be affected by the use of different categories of glucose-lowering therapies. SN - 1349-7235 UR - https://www.unboundmedicine.com/medline/citation/23648711/Increased_risk_of_gastrointestinal_malignancy_in_patients_with_diabetes_mellitus_and_correlations_with_anti_diabetes_drugs:_a_nationwide_population_based_study_in_Taiwan_ L2 - https://joi.jlc.jst.go.jp/DN/JST.JSTAGE/internalmedicine/52.8276?from=PubMed DB - PRIME DP - Unbound Medicine ER -